Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

Pathol Oncol Res. 2023 Jan 30:29:1610989. doi: 10.3389/pore.2023.1610989. eCollection 2023.

¹ Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
² Departmentof Oncology, Dongying City People's Hospital, Dongying, China.
³ Department of Pathology, Dongying City People's Hospital, Dongying, China.
⁴ Department of Microbiology and Immunology, Tulane University, New Orleans, LA, United States.
⁵ Department of Urology Surgery, Dongying Hospital of Traditional Chinese Medicine, Dongying, China.
⁶ Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
⁷ Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
⁸ Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.

Abstract

[This corrects the article DOI: 10.3389/pore.2022.1610638.].

Keywords: PD-1/PD-L1; immune checkpoint inhibitors; immunotherapy; lynch syndrome; microsatellite instability; urothelial carcinoma.